New Delhi: Made-in-India neutralizes several variants of the COVID-19 vaccine, covaxin, SARS-CoV-2 and effectively works against the dual mutant strain,
the Indian Council of Medical Research (ICMR) said today.
Covaxin of Bharat Biotech has received the Emergency Use Authority (EUAs) for COVID-19 treatment in India and
many countries around the world, with another 60 in the process.
ICMR tweeted, Covaxin neutralizes covid against multiple variants of SARS-CoV-2 and also neutralizes double mutant strains.
Also Read: Before the May 1 KVV-19 vaccination campaign, the Serum Institute shared the price of ‘Covisheild’, see rates here
The ICMR-National Institute of Virology has successfully isolated and cultured several forms of concern for the SARS-CoV-2 virus:
B.1.1.7 (UK version), B.1.1.28 (Brazilian version) and B.1.351 ( South Africa) vary).
The top health research officer said that ICMR-NIV has demonstrated the neutralization potential of covaxin against the UK variant and the Brazilian variant.
ICMR-NIV has been successful in isolating and promoting the double mutant strain of B.1.617 SARS-CoV-2, recently identified in some regions of India and many other countries, ICMR said.
“Covaxin has been found to effectively neutralize the double mutant strain,” it said.
Like our Facebook page